British Liver Trust supports Obesity Health Alliance Position Statement on Health Inequalities

February 21, 2023

The Obesity Health Alliance (OHA) is a coalition of 50 health organisations including the British Liver Trust, British Heart Foundation, Cancer Research UK, Diabetes UK the British Medical Association and medical royal colleges and other health charities. The published statement outlines the known evidence base for the relationship between overweight and obesity and health inequalities, and the recommendations supported by the OHA to address health inequalities through action to reduce the prevalence of obesity.

Read the full statement.

Summary

  • Excess weight leads to a large number of diseases that cause significant mortality and morbidity, including type-2 diabetes, cardiovascular disease (CVD), liver disease, many types of cancer, musculoskeletal conditions and poor mental health. Moderate to extreme obesity can shorten life expectancy by 3-10 years.
  • Overweight and obesity prevalence is high across the UK population, but there are stark inequalities across ages, geographical areas, genders, ethnic groups and for those with both mental and physical disabilities. These inequalities are growing, as rates of children with obesity are increasing significantly faster in communities with high deprivation levels compared to those with low deprivation levels.
  • To address these eminently avoidable health inequalities a comprehensive, evidence-based approach is needed that prioritises:
    1. Reformulation of unhealthy food and drink products, which will have a disproportionately beneficial impact on the health of people on lower incomes.
    2. Restrictions on marketing of unhealthy food and drink products, which are currently disproportionately directed at those on lower income, as well as appropriate monitoring and enforcement of these policies.
    3. Further evidence-based measures that target the key drivers of excess weight should be taken forward and well-funded, including early years interventions and improved access to weight management services.

Read the full statement.

More news

NICE recommends maralixibat for treatment of cholestatic pruritus in Alagille Syndrome

NICE recommends maralixibat for treatment of cholestatic pruritus in Alagille Syndrome

Liver UK is delighted to hear Friday’s announcement from the National Institute for Health and Care Excellence (NICE) that they recommend maralixibat for use within the NHS for treating cholestatic pruritus (severe itch) due to ...
Liver UK visit the Senedd

Liver UK visit the Senedd

We brought our Love Your Liver Roadshow to Senedd Cymru on Tuesday 6th October, to highlight the urgent need for earlier detection and improved care in Wales. By attending with our Love Your Liver Unit, we were able to demonstrate our ...
Millions living with fatty liver disease without knowing it, UK study suggests

Millions living with fatty liver disease without knowing it, UK study suggests

New research released today at the UK’s leading liver conference shows that millions of people in the UK are living with fatty liver disease without a diagnosis. Researchers presenting new data at the British Association for the Study ...
No results found.
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.